A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 μg b.i.d.) as an active control - ND

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2008
This article has no abstract
Epistemonikos ID: fc045f7bd6837ec4cd67995869bb87b3bf1380cb
First added on: Apr 16, 2025